Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-10-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：独立董事关于第二届董事会第十九次会议相关事项的独立意见
Regulatory Filings
2021-10-29 Chinese
美迪西：首次公开发行战略配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares (strategic placement shares) following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period, shareholder commitments, and includes verification from the sponsoring institution. The document does not contain financial statements or detailed financial performance data but is a formal notice about share circulation status post-IPO. This fits the category of Share Issue/Capital Change announcements, specifically about restricted shares becoming tradable after a lock-up period.
2021-10-28 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司首次公开发行战略配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the listing and circulation of restricted shares from a company's initial public offering (IPO) on the Shanghai Stock Exchange's STAR Market. It references regulatory approvals, share issuance details, lock-up periods, shareholder commitments, and compliance with relevant laws and regulations. The document is not an announcement of a report publication but a substantive verification opinion related to share circulation post-IPO. This type of document is a regulatory compliance verification related to capital market activities, specifically concerning share circulation after an IPO. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a direct announcement of voting results or a capital raising update but a formal verification opinion on share circulation compliance. The closest fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-10-28 Chinese
美迪西：关于股东减持股份数量过半暨减持股份进展公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from Shanghai Medicilon Inc. regarding the progress of a shareholder share reduction plan. It details the shareholders involved, the number of shares held and reduced, the reduction methods, and the impact on company control. The document is relatively short (3105 characters) and focuses on the update of a shareholding reduction event rather than financial results or management commentary. It does not contain financial statements or detailed financial analysis. The content fits the category of a Major Shareholding Notification, which covers notifications of changes in significant share ownership levels, including reductions. Therefore, the appropriate classification is MRQ (Major Shareholding Notification).
2021-09-28 Chinese
北京金诚同达（上海）律师事务所关于上海美迪西生物医药股份有限公司2021年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedural compliance of a company's 2021 first extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or performance data but focuses on the legal validation of the meeting and its resolutions. This type of document is typically associated with shareholder meeting legal opinions and voting results announcements. Given the detailed voting results and the nature of the document, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a brief announcement but a full legal opinion on the voting process and results, supporting a high confidence classification as DVA.
2021-09-03 Chinese
美迪西：第二届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the approval of a restricted stock grant under a stock incentive plan. It includes details about the meeting date, attendance, legal compliance, and the voting results on the stock grant proposal. The content focuses on board/management decisions and approvals rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor an earnings release or proxy statement. The document is a management/board announcement about internal governance and incentive plan approval, fitting the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2021-09-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.